ga

Skip to content

My Files [0]

These are the files you have added to your collection.

  • You don't have any documents yet, feel free to browse the website and add documents.

CADTH » Search All Products » Common Drug Review » CDR Update » CDR Update - Issue 48

CDR Update - Issue 48

Recent CDR Recommendations

The following recommendations were issued through CADTH’s Common Drug Review program from January 1 to March 31, 2008.

Drug Name
(Brand Name)

 

Indication
(Condition)

Recommendation
Released

Final CEDAC Recommendation

(Click link
to view full recommendation and reasons for recommendation)

acamprosate calcium (Campral)

Alcohol abstinence

2008-03-27

List with criteria/condition

ranibizumab (Lucentis)

Age-related macular degeneration (AMD)

2008-03-27

List with criteria/condition

aprepitant (Emend)

Chemotherapy induced nausea and vomiting

2008-02-20

List with criteria/condition

delta-9-tetrahydrocannabinol/ cannabidiol (Sativex)

Cancer pain (adjunctive analgesia to maximum tolerated strong opioids)

2008-02-20

Do not list

lanthanum carbonate hydrate (Fosrenol)

Hyperphosphatemia, end-stage renal disease

2008-01-30

Do not list

sitaxsentan sodium (Thelin)

Pulmonary arterial hypertension (WHO class II and III)

2008-01-30

Do not list

posaconazole (Spriafil)

Aspergillus and Candida infections

2008-01-30

Do not list

Feedback

We’re interested in your feedback. Tell us what you think of our CDR Update e-bulletins. Comments on the CDR section of CADTH’s web site or the CDR Drug Database are also welcome.